Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
Warlow
Charles
C
University of Edinburgh, Edinburgh, Scotland, UK. cpw@skull.dcn.ed.ac.uk
D001241:Aspirin / Q000191:economics / Q000627:therapeutic use*; D000077144:Clopidogrel; D004176:Dipyridamole / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin